Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists

We previously reported the design and synthesis of a small-molecule drug conjugate (SMDC) platform that demonstrated several advantages over antibody–drug conjugates (ADCs) in terms of in vivo pharmacokinetics, solid tumor penetration, definitive chemical structure, and adaptability for modular synt...

Descripción completa

Detalles Bibliográficos
Autores principales: Debnath, Sashi, Hao, Guiyang, Guan, Bing, Thapa, Pawan, Hao, Justin, Hammers, Hans, Sun, Xiankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266369/
https://www.ncbi.nlm.nih.gov/pubmed/35806163
http://dx.doi.org/10.3390/ijms23137160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266369/
https://www.ncbi.nlm.nih.gov/pubmed/35806163
http://dx.doi.org/10.3390/ijms23137160

Ejemplares similares